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respond to physiological emotional arousal, and increase 
their pacemaker function.11 The concept is to have the 
electronic pacemaker provide a bridge to biological 
pacing therapeutics, until there is more solid evidence for 
the safety and efficacy of this revolutionary novel 
approach.  
Whether the end result of the application of all these 
preliminary data will be a clinically applicable biological 
pacemaker remains to be proven. Although proof of 
concept has been demonstrated, there is still a long way 
to go and many obstacles to overcome before its safe and 
reliable clinical application. First, one needs to identify 
the ideal candidate pacemaker cells, and second to make 
headway in fine-tuning the behavior of these pacemaking 
cells, while finally monitoring and controlling the 
interactions between the pacemaker and host 
myocardium. Thus, there is still need for development of 
new technologies and more testing in the animal 
laboratory to enhance our understanding of mechanisms 
that control gene expression and cell coupling until the 
biological pacemaker becomes a feasible and realistic 
project. Meanwhile, electronic pacemaker systems have 
proven their value, while they are still rapidly evolving 
and for now remain the main and only player in the field.  
As the inventor himself, Dr Michael Rosen,12 has put 
it, in order to “see biological pacemaking in our lifetime”, 
the following are needed: “For virus or stem cell, we need 
evidence that it is superior to the electronic pacemaker in 
terms of adaptability to the body’s physiology and 
duration of effectiveness; evidence regarding long-term 
incidence of inflammation, infection, rejection, neoplasia; 
evidence for/against long-term proarrhythmic potential; 
localization at site of implantation vs migration to other 
sites; other toxicity; optimization of delivery systems”. 
“For stem cell (embryonic, mesenchymal), we need 
evidence regarding persistence of the administered cell 
type vs differentiation into other cell types; in the latter 
event, evidence regarding persistence of pacemaker 
function (current and coupling)”.  
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Atrial fibrillation (AF) is the most common sustained 
cardiac arrhythmia in the general population, affecting 
about 0.4% of the general population. Its prevalence 
increases with age reaching 15% in adults over 70 years 
of age.1 During the past decade, as techniques and 
technologies have improved, catheter ablation of AF has 
become a standard and effective therapy for patients with 
symptomatic and drug-refractory AF. The improved 
three-dimensional electroanatomic mapping systems and 
the induction in the clinical practice of other ablation 
techniques, such as cryoablation, have contributed to the 
worldwide increase of the number of ablation procedures. 
Catheter ablation seems to be superior to antiarrhythmic 
drug therapy (ADT) which is also associated with 
potential toxic or proarrhythmic effects after long term 
use. The recently presented data from RAAFT 2 study, 
showed that 55% of the patients who had randomized to 
AF ablation had had a recurrence compared to 72%, of 
those who had received ADT after 2 years follow up.2 For 
the first time, the 2012 updated guidelines from the 
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European Society of Cardiology, recommend catheter 
ablation as the first line therapy in selected patients with 
paroxysmal AF alternative to ADT (class IIa, level B).3 
The main target of the AF catheter ablation is the 
circumferential electrical isolation of the pulmonary veins 
(PVs) ostium or antrum. In some patients suffering from 
persistent AF, a more aggressive strategy is adopted, 
including left atrial substrate modification with linear 
ablation or rarely with lesions in other anatomical 
structures as right atrium, superior or inferior vena cava, 
fossa ovalis, left atrial appendage and coronary sinus or 
the ligament of Marshall.3  
Success rates for AF ablation depend on a large 
number of factors. Of great importance, are the type of 
AF (paroxysmal, persistent, or long-standing persistent 
AF), the presence or absence of comorbidities, such as 
uncontrolled hypertension, obesity and sleep apnea, the 
definition of success, and the duration of follow-up.3 The 
fact is that the single procedure results for AF catheter 
ablation, are a bit disappointing as a large number of 
patients, about 20% - 40%, present with early or late 
recurrences of AF.4 These episodes are common, during 
the first 2 or 3 months after the ablation procedure and 
most studies have reported that the main problem is the 
electrical reconduction of the previously isolated PVs. 
The short term use of ADT, after AF ablation during the 
first three months after the procedure, seems to reduce the 
incidence of the early recurrence episodes, but not the late 
recurrence after the 6 months.3 Sorgente et al suggested 
that after 6 years of follow up in patients with mainly 
persistent AF resistant to ADT, 41% of them underwent a 
second ablation procedure. Only 23% after the first 
procedure were free of AF after 6 years of follow up in 
contrast to 39% after the last procedure. Moreover, 
multivariate regression analysis showed that the only 
clinical factor that affected the possibility of recurrence, 
was the presence of non paroxysmal AF.5 Similar results 
were obtained by 5 years follow up in patients after AF 
ablation, to whom late recurrence rate was associated 
independently to the presence of persistent AF and 
diabetes mellitus.6 Thus, the most predictive factor for the 
late recurrence, seems to be the presence of persistent AF. 
Older patients with cardiomyopathy, ischemic or 
dilatative, diabetes mellitus and large atrium, are more 
prone to recurrences. The redo ablation procedures, 
always target to the circumferential re-isolation of the 
PVs or to new arrhytmogenic foci outside the PVs. 
Most of the published studies about the AF ablation 
efficacy, presented data from short term follow up in less 
than 12 months. The outcomes of catheter ablation were 
better compared to ADT in the majority of these 
randomized trials.  During one year follow up of 198 
patients with paroxysmal AF enrolled in the APAF study, 
93% of them who underwent catheter ablation were free 
of symptoms compared to 35% who received ADT.7 
Similarly, one year data from the A4 study showed that 
89% of patients had no recurrence after catheter ablation 
compared to 23% enrolled in the ADT group.8 Moreover, 
a meta-analysis of four randomized trials revealed the 
superiority of the ablation compared to ADT (75.7% vs. 
18.8%, P<0.001).9 
Data in the literature is not so much as regards the 
long term results of AF catheter ablation and mostly are 
derived from single center as well as multicenter studies 
involving patients with paroxysmal and persistent AF. 
Table 1 presents the most important studies published the 
last years.6,10-16 Patients in the majority of the trials didn’t 
receive long-term ADT and they mostly underwent more 
than one procedure. Gaita et al10 enrolled 204 patients 
with either paroxysmal or persistent/permanent AF and 
they reported that PV isolation plus linear left atrial 
ablation without ADT is superior to the PV isolation after 
the first and second procedure in maintaining sinus 
rhythm at 3 years follow up. Pulmonary vein isolation has 
better long term outcomes in patients with paroxysmal 
AF. One hundred patients who underwent AF ablation 
were followed up for 39±10 months after their last 
procedure. The mean time to AF recurrence was 6 ± 10 
months. After a single procedure, sinus rhythm was 
maintained at long-term follow-up in 49% patients 
without ADT. With a repeat procedure 57% of the 
patients had stable sinus rhythm without ADT and 82% 
with ADT.17  
In the study of Wokhlu et al12 factors associated 
independently to very late recurrence after 6 years, were 
the persistent AF and the wide area circumferential PV 
isolation. In this study left atrial diameter >45 mm was 
also associated independently with recurrence in patients 
with paroxysmal AF. Recently, Chao et al16 reported that 
CHADS2 score ≥3 was also an independent predictor in 
patients with non paroxysmal AF of recurrences. Patients 
who undergo a second ablation procedure have better 
long term success rates, than after the first ablation. Data 
from the group of Haissaguerre shows, that after 5 years 
of follow up in 100 patients arrhythmia – free rates after a 
single catheter ablation procedure were 40%, 37%, and 
29% at 1, 2, and 5 years, respectively, with most 
recurrences over the first 6 months.15 On the contrary, for 
the same follow up periods the rates following the redo – 
ablations, were 87%, 81%, and 63%, respectively.15 As 
far as the patients with left ventricular systolic 
dysfunction are concerned, they have not participated in 
the majority of these clinical studies. However, a recent 
meta-analysis suggested that AF ablation improves left 
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ventricular systolic function by 11%, but patients with 
coronary heart disease benefit less compared to others.18 
We will have more specific results, from two on going 
multicenter trials (CASTLE-AF and AMICA) which 
evaluating the benefit of AF catheter ablation in patients 
with heart failure. Moreover, we have to notice, that there 
is not enough data about the long term efficacy of AF 
cryoablation. The only prospective randomized study in 
this field is the STOP-AF trial that enrolled 245 patients, 
with 163 randomized to cryoballoon treatment and 82 
patients randomized to ADT [279]. After a mean follow-
up of 9 months, 69.9% of patients treated with 
cryoballoon ablation, were free from AF compared with 
7.3% of patients on antiarrhythmic drug therapy. 
Nineteen percent of the patients required a repeat 
procedure and 12% remained on ADT.19 
The incidence of stroke episodes after AF ablation, is 
a very important parameter for the monitoring of these 
patients. A multicenter study enrolled 3,355 patients of 
whom 2,692 discontinued oral anticoagulation therapy 
(OAT) 3 to 6 months after ablation and 663 remained on 
OAT after this period. Follow up period was more than 2 
years and 0.07% of the first group patients versus 0.045% 
of the second one had an ischemic stroke.20 The incidence 
of the stroke seems to be higher, during the first two 
weeks after the procedure (0.9%) and lower later (0.1% 
for every year). The incidence after the discontinuation of 
the OAT 3 months after the ablation did not differ 
significantly between the patients without risk factors and 
those with ≥1 risk factor. 21 
The fact is that catheter ablation has become an 
important and widely used treatment modality for patients 
with symptomatic AF. The target remains the PV 
isolation or the left atrium modification using mostly 
radiofrequency energy with the support of the 
electroanatomical mapping systems. Patients may require 
more than one procedure and this can improve the 
success rate to around 50% to 70%. Of course the hope is 
to avoid the repetition of the procedures and this could 
maybe happen in the near future, with the evolution of the 
technology. Moreover, we are waiting the results from the 
CABANA trial which is expected to be completed in 
2015 and about 3,000 patients will be enrolled, 
comparing the efficacy of the ablation versus ADT during 
a follow up period of 5 years.   
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Table 1. Most Important Studies for Long-term Results of AF Catheter Ablation 
   
Study No. of patients AAD Ablation strategy FU Success rate 
Gaita F et 
al10 
204 pts(PAF & 
persAF/permAF) no PVI or PVI+ LL 3 years 
PAF 
PVI:  1st 29%, 2nd 62% PVI+LL: 1st  53%, 2nd 85% 
persAF/permAF 
PVI: 1st 19%, 2nd 39% PVI+LL: 1st 41%, 2nd 75% 
Katritsis 
et al11 
39 pts (14 pts 1 abl., 
19 pts 2 abl. & 6 pts 
3 abl.) PAF 
33 pts Amio- 
for 6 weeks 
after abl. 
PVI 42.2±6 months 21.4% for 1 abl, 52.6% for 2 abl. & 66.7% for 3 abl. 
Bhargava 
et al12 
1404 pts(728 PAF, 
676 NPAF) 
pts without 
redo-ablation  
PVI & SVC 
guided by ICE 
57±17 
months 
PAF: 1st 77.6%, 2nd 92.4% 
(without ADT) 
NPAF: 1st 67.2%, 2nd 84% 
(without ADT) 
Wokhlu et 
al6 
774 pts (55% PAF, 
45% persAF) yes 
PVI (38%), 
WACA (62%) 
3.0±1.9 
years 
PAF: 71%, pers AF: 61%. Recurrence from 1 to 2.5 years 
increased by 20% in persAF vs. 12% in PAF. 
Tzou et 
al13 
239 pts (85% PAF 
& persAF), 123 
were free from AF 1 
year after one abl. 
procedure 
no PVI  &  non PV triggers 
5.9±1.5 
years 
AF free were 85% at 3 yrs and 71% at 5yrs, 7% per year 
recurrence rate after the 1st year 
Ouyang et 
al14 161 pts with PAF 
3 months after 
ablation PVI 
median 
4.6 
years 
75 pts were in SR after the 1st ablation, 66 pts 2nd ablation, 
12 pts 3rd abl. 79.5% of the pts had SR during FU (median 
1 procedure) 
Weerasoo
riya et al15 100 pts (64% PAF) 
Discontinued 
after 1 month 
with stable SR 
PVI + CTI + LL 
(persAF) 5 years 
AF free were 40%, 37%, and 29% at 1, 2, 
and 5 years (median 2 procedures per patient) 
Chao et 
al16 88 pts with NPAF no 
PVI + LL + 
CFAE + 
nonPVI foci
mean  
36.8 
months 
71.6% had recurrence , 
47.7% after the 2nd ablation  & 51.1% after the 3rd ablation 
were free of recurrence 
 
AAD = antiarrhythmic drug (therapy); abl = ablation; AF = atrial fibrillation; CFAE: complex fractionated atrial electrograms; CTI = 
cavo-tricuspid isthmus; FU = follow-up; ICE = intracardiac echocardiography; LL = left linear; NPAF = non paroxysmal atrial 
fibrillation; PAF = paroxysmal atrial fibrillation, persAF = persistent atrial fibrillation; pts = patients;  PV = pulmonary veins; PVI = 
pulmonary vein isolation; SR = sinus rhythm; SVC = superior vena cava; WACA = wide antrum circumferential ablation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
